
Morgan Stanley lowered the firm’s price target on BridgeBio Oncology (BBOT) to $12 from $13 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics | 1.81 | -10.58 | -85.39% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.81 | -85.39% |

Morgan Stanley lowered the firm’s price target on BridgeBio Oncology (BBOT) to $12 from $13 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

Piper Sandler analyst Biren Amin lowered the firm’s price target on BridgeBio Oncology (BBOT) to $15 from $21 and keeps an Overweight rating on the shares. The firm notes the

Reports cash, cash equivalents, and marketable securities totaling $315.3M as of September 30, 2026, which is expected to provide cash runway into 2029. “With a strong balance sheet, multiple data

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BridgeBio Oncology (BBOT) to $13 from $18 and keeps an Overweight rating on the shares. Published first on TheFly

Oppenheimer analyst Mazahir Alimohamed lowered the firm’s price target on BridgeBio Oncology (BBOT) to $16 from $22 and keeps an Outperform rating on the shares. The firm believes the September

JPMorgan lowered the firm’s price target on BridgeBio Oncology (BBOT) to $23 from $25 and keeps an Overweight rating on the shares. The firm updated the company’s model following the

Leerink analyst Andrew Berens lowered the firm’s price target on BridgeBio Oncology (BBOT) to $27 from $39 and keeps an Outperform rating on the shares. The firm notes BridgeBio has

Raymond James analyst Sean McCutcheon lowered the firm’s price target on BridgeBio Oncology (BBOT) to $22 from $24 and keeps an Outperform rating on the shares. BridgeBio’s strategic reprioritization is

Stifel lowered the firm’s price target on BridgeBio Oncology (BBOT) to $15 from $23 and keeps a Buy rating on the shares after the company announced a pipeline reprioritization and

Canaccord lowered the firm’s price target on BridgeBio Oncology (BBOT) to $20 from $23 and keeps a Buy rating on the shares. The firm updated its model after the company
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 18, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Assigned | Sep 18, 2026 | ||||
| buy | Reiterated | Sep 9, 2026 | ||||
| buy | Reiterated | May 1, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $145.25M | $-0.44 | $0.00 | 0.03 | -0.00 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.